Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

NCT06136910 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Untreated Advanced Non-small Cell Lung Cancer

Interventions

DRUG: Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy

Sponsor

Fujian Cancer Hospital